anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methods and systems for anesthetizing a portion or all of a patient's maxillary dental arch using a nasal delivered anesthetizing composition. The process generates anesthesia sufficient for facilitation of operative dentistry, endodontics, periodontics or oral surgery for teeth of the maxillary arch. The dental nasal spray process consists of inserting one or more dispensing devices through the patient's nostril and delivering metered dosages of anesthetic solution or gel into the nasal cavity. The process may utilize a single solution which is a mixture of anesthetic agents, vasoconstricting agents and other physiological inert agents or two separate solutions, wherein one solution contains the vasoconstricting agents and the other solution contains the anesthetic agents. Anesthetic diffusion through the thin walls of the nasal cavity allows for the blocking of nerve impulses originating from the maxillary dentition and surrounding tissues. Anesthesia of specific oral regions such as right versus left sides of the dental arch, anterior versus posterior teeth, and soft tissue anesthesia may be controlled through modification of the dosage volume and the selection of right or left nostril insertion and agent delivery.
Cognitive decline represents a pathological condition for elderly with negative consequences on social functioning and independent living. To reduce the incidence of cognitive deficits in mild cognitive impairment (MCI), treatments that prevent or delay dementia are needed. The main objective of STRENGTH Project, is the assessment of the effects of a comprehensive intervention in 300 subjects with MCI, finalized to improve functional, biochemical, cognitive outcomes and psycho-social aspects. The study uses a multidisciplinary approach, has a 3-year duration, and includes 3 follow-up phases. Participants will be assigned to: a) Experimental group, which will undergo a multimodal intervention for improving cognitive outcomes, functional status and mobility. Treatment will include sessions of Adapted tango, music therapy, engagement in social activities, comprehensive cognitive intervention and psycho-education for 6 months; or b) Control group, which will receive psycho-education and advice on healthy life-style for 6 months. Cognitive and psycho-social outcomes, functional, cardiovascular status, life-style characteristics, biochemical determination, will be evaluated at baseline and longitudinally. Our hypothesis is based on expectation that the proposed could improve cognitive, functional outcomes and quality of life, with a positive impact on prevention of onset of dementia and cognitive decline in MCI subjects.
Certain frequent gynecological pathologies are emerging in the literature as new venous thrombotic risk factors independently of hormonal treatment. Indeed, in endometriosis, the prevalence of which is estimated to be around 10%, biological data are in favor of hypercoagulability. Only one epidemiological study has analyzed this parameter. It is a Japanese cohort study in 103,070 pregnant women including 77 VTE during pregnancy. Endometriosis and recurrent pregnancy loss (RPL) were identified as risk factors for VTE (OR: 2.70 (95%CI, 1.21-6.00) for endometriosis and 6.13 (95% 2.48-15.16) for RPL. In polycystic ovary syndrome (PCOS), whose prevalence is estimated at 7-12%, the associated risk of VTE is better known (OR 1.89, 95%CI 1.60-2.24) and was the subject of a recently published meta-analysis in which the principal investigator collaborated. To the investigators knowledge, no study describes the prevalence of gynecological pathologies in women with VTE.

Concerning hormonal contraception, estrogen-progestin contraception (EPC) is widely used in France and is associated with an increase in the risk of VTE of a factor of 3 to 6. After a venous thrombotic episode, EPC is contraindicated, and non-hormonal or progestin-only contraception (POC) can be used. Nevertheless, to date, few studies have focused on the management of hormonal contraceptive treatment at the time of a VTE episode. Moreover, the contraceptive options presented to patients are often based on multiple actors (vascular physicians, gynaecologists, midwives, general practitioners, etc.) and the experience of the VTE episode, for both patients and prescribers, may influence the contraceptive options proposed or chosen, as well as their compliance.
BACKGROUND: Hope is an important resource that helps patients and families thrive during difficult times. Although several studies have highlighted the importance of hope in different contexts, its specific manifestations in the realm of advanced chronic illness need further exploration. In this study, we sought to elucidate the intricate interplay between the construct of hope and the lived experience of advanced chronic illness within patient-caregiver dyads. Our objectives were (a) to explore the dyadic experience of hope as a changing dynamic over time for patients living with advanced chronic illness and their informal caregivers and (b) to evaluate variations of hope and symptom burden across time.
METHODS: We conducted a longitudinal mixed-methods study with a convergent design between December 2020 and April 2021. Patients living with advanced chronic illness and informal caregivers participated as a dyad (n = 8). The Herth Hope Index scale was used to measure dyads' level of hope and the Edmonton Symptom Assessment System was used to measure patients' symptom burden. Descriptive statistics were undertaken. A thematic analysis as described by Braun and Clarke was conducted to analyze dyadic interview data. Dyads' experience of hope was described by using the six dimensions of hope in the Model of Hope of Dufault and Martocchio.
RESULTS: Dyadic scores of hope and patients' symptom burden were stable over time. The constructs of hope in dyads included "Living one day at the time," "Having inner force/strength," and "Maintaining good health." Changes in patterns of hope were captured for each dyad in their transition over time. Data converged for all dyads except one.
CONCLUSIONS: The findings of our study show a constant presence of hope even in the face of adversity. Healthcare professionals must find ways to promote hope in dyads of patients living with advanced chronic diseases. Nurses play a pivotal role; dyadic interviews should be promoted to create a safe space for both patients and informal caregivers in order to share experiences. More research is needed to address patients' and informal caregivers' hope in chronic illness because current hope-based interventions primarily target cancer diagnoses.
Dosage should be individualized for maximum beneficial effect. While the usual daily dosages given below will meet the needs of most patients, there will be some who may require higher doses. In such cases dosage should be increased cautiously to avoid adverse effects. ADULTS: USUAL DAILY DOSE Management of Anxiety Disorders and Relief of Symptoms of Anxiety Depending upon severity of symptoms – 2 mg to 10 mg, 2 to 4 times daily Symptomatic Relief in Acute Alcohol Withdrawal 10 mg, 3 or 4 times during the first 24 hours, reducing to 5 mg, 3 or 4 times daily as needed Adjunctively for Relief of Skeletal Muscle Spasm 2 mg to 10 mg, 3 or 4 times daily Adjunctively in Convulsive Disorders 2 mg to 10 mg, 2 to 4 times daily Geriatric Patients, or in the presence of debilitating disease 2 mg to 2.5 mg, 1 or 2 times daily initially; increase gradually as needed and tolerated PEDIATRIC PATIENTS: Because of varied responses to CNS-acting drugs, initiate therapy with lowest dose and increase as required. Not for use in pediatric patients under 6 months. 1 mg to 2.5 mg, 3 or 4 times daily initially; increase gradually as needed and tolerated.
A coating product comprising an aqueous chromic composition, comprising a colour-change component, a binder dispersed in an aqueous (water) solution, where the product further comprises i) a colourant dispersed or dissolved in the aqueous composition, or ii) a separate aqueous solution comprising a colourant adapted for use with the aqueous chromic composition to provide an underlaying layer comprising colourant underlying the colour-change component. The colour change component may be a thermochromic liquid crystal, encapsulated liquid crystal, leuco, hydrochromic, vapochromic, solvatochromic, ionochromic, or halochromic component. The colourant may comprise a water-soluble dye, which is dark in colour, e.g. carbon black. The binder may be selected from non-ionic hydrophobically modified ethoxylated urethane (HEUR), acrylic polymer, styrene/acrylate, styrene/acrylate/ammonium methacrylate copolymer, epoxy resin, or polyurethane. It may have a separate aqueous top-coat comprising a UV absorbing agents and water. There may also be a glycol based rheology modifier. Also provided is a dried or cured coating comprising a colour-change component dispersed in a continuous phase comprising dried or cured binder from an oligomer or monomer, and an initiator. The composition may be used to coat nails.
In this study, very preterm infants receive High-Flow Nasal Cannula therapy immediately after birth. The intervention includes placental transfusion, followed by administering High-Flow Nasal Cannula at a flow rate of 8 l/min along with intermittent tactile stimulation. Criteria for switching to Continuous Positive Airway Pressure or Positive Pressure Ventilation are established for cases of persistent bradycardia or low SpO2.
HPV vaccine rates remain lower than rates for other adolescent vaccines. Missed opportunities (MOs) are healthcare visits during which a patient is eligible, but does not receive a vaccine. MOs for vaccination contribute strongly to low HPV vaccination rates. This trial focuses on period 2, the addition of performance feedback in the presence of communication skills training. Arm-1 intervention study practices add performance feedback (period 2), building upon their prior training in communication skills (period 1); Arm-2 comparison study practices continue delivering standard of care. During this period, the investigators will be measuring captured opportunities - the inverse of MOs, or visits when an eligible patient receives a vaccine. Providers rarely receive feedback to track their captured opportunities, but feedback has been shown to be an effective tool. Performance feedback reports will pull from electronic health record (EHR) data, and will compare participants performance to their own previous performance and those of others. Throughout the intervention participants will also receive weekly text message mini-lessons that will remind participants of the project.
Participants will receive the p24CE1/2 pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Month 1. They will receive the p24CE1/2 pDNA vaccine plus the p55\^gag pDNA vaccine and the IL-12 pDNA adjuvant at Months 3 and 6.
PURPOSE:To obtain a black pigment which is excellent in applicability such as covering power and spread and causes neither agglomeration when incorporated in a cosmetic preparation nor color separation when applied onto the skin, by forming a thin interlayer comprised of a metal oxide or its hydrate on the surface of an inorg. and/or organic powdery material and then depositing triiron tetroxide on the interlayer. CONSTITUTION:A thin interlayer comprised of a metal oxide or its hydrate is first formed on the surface of an inorg. and/or org. powdery material. An aq. soln. contg. a ferrous (II) salt and an oxidizing agent is added in portions in the presence of a base to an aq. suspension contg. the inorg. and/or powdery material coated with the interlayer. Thus, triiron tetroxide is deposited on the surface of the inorg. and/or org. powdery material coated with the interlayer, thereby coating it with the triiron tetroxide. The percentage coating of the interlayer is about 0.01-20wt% based on the weight of the powdery material. Examples of the metal oxide or its hydrate employed as the interlayer include iron oxide, aluminum oxide, nickel oxide, chromium oxide and their hydrates.
Intravenous administration of EE-TP. The starting dose will be Dose Level 1, with potential subsequent dose levels of Dose Level 2 and Dose Level 3 dependent on whether metabolic correction is achieved or not.
Aspects of the disclosure are directed to a hair cosmetic composition comprising about 4 to about 32 wt. % of two or more polyols, such as about 1 wt. % or more of a glycol and about 2 wt. % or more of glycerin; about 0.5 to about 10 wt. % of a nonionic surfactant; about 2 to about 25 wt. % of a fatty ester; about 0.1 to about 7 wt. % of a film former; about 0.1 to about 5 wt. % of a thickening agent; about 0.5 to about 12 wt. % of an oil; and water, wherein all weight percentages are based on the total weight of the hair cosmetic composition.
Risk Summary

Colchicine is present in human milk (see Data). Adverse events in breastfed infants have not been reported in the published literature after administration of colchicine to lactating women. There are no data on the effects of colchicine on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for GLOPERBA and any potential adverse effects on the breastfed infant from GLOPERBA or from the underlying maternal condition.

Data

Limited published data from case reports and a small lactation study demonstrate that colchicine is present in breastmilk. A systematic review of literature reported no adverse effects in 149 breastfed children and advised to reconsider breastfeeding if the infant has diarrhea. In a prospective observational cohort study, no gastrointestinal or other symptoms were reported in 38 colchicine-exposed breastfed infants.
PROBLEM TO BE SOLVED: To effectively suppress the interlayer debonding of a multilayer tablet without involving complicated processes including increasing the amount of vehicle or binder by bringing the ratio for the respective average sizes of the granules in two layers being in mutual contact in the multilayer tablet within a specific range. SOLUTION: The subject method for suppressing the debonding of a multilayer tablet comprises bringing the ratio of the average size of granules 4 constituting one of two layers 2,3 being in mutual contact in a multilayer tablet 1 to that of granules 5 constituting the other layer to (1:2) to (1:50). The above multilayer tablet is such one as to contain an ordinary physiologically active ingredient such as an active ingredient of antipyretic analgesics or cold remedies (e.g. aspirin), vitamin (e.g. vitamin B1), antacid (e.g. aminoacetic acid), anti-inflammatory agent (e.g. naproxen), another active ingredient (e.g. diphenidol hydrochloride), crude drug or Chinese herb medicine (e.g. Ephedra sinica), mineral, amino acid, peptide or protein (e.g. insulin).
Gastroparesis is a functional disease affecting 4% of the population, which is consecutive to diabetes in 30% of cases and considerably alters the patients' quality of life. The diagnosis is based on gastric fullness symptoms, endoscopy and gastric emptying scintigraphy. The therapeutic alternatives including drug therapies (Metoclopramide, Erythrocin), surgery (Electric gastric stimulation) or endoscopy (Botulinic toxin), are insufficiently effective. Two surgical series suggested an interesting efficacy of laparoscopic pyloroplasty, which remains invasive for a motility disorder. More recently, an US team performed the first case of G-POEM with an excellent outcome and no adverse event. This promising result was confirmed by a Brazilian case, a short retrospective series (7 patients) and the first European case performed and published by our team that has performed 5 cases since. Based on experience, it is proposed a prospective monocentric study to evaluate the efficacy of the G-POEM technique on refractory gastroparesis. This study will include 40 patients on a period of three years, whom suffer from refractory gastroparesis, confirmed by clinical evaluation (GCSI and analogic visual scale), upper GI endoscopy and gastric emptying scintigraphy at the inclusion.
C. Laboratory Tests

1\. Women with disseminated breast carcinoma should have frequent determination of urine and serum calcium levels during the course of androgen therapy (see WARNINGS).

2\. Because of the hepatotoxicity associated with the use of 17-alpha-alkylated androgens, liver function tests should be obtained periodically.

3\. Hemoglobin and hematocrit should be checked periodically for polycythemia in patients who are receiving high doses of androgens.
The invention relates to the technical field of data processing, and discloses a thoracic surgery image analysis method of big data. The collected data is then preprocessed, and shape, texture, and color features are then extracted from the preprocessed thoracic images. Then, an image recognition model is established based on the extracted data features by using a machine learning method, and training, evaluation and optimization are performed to improve the accuracy of the model. The optimized model is embedded into a thoracic imaging diagnostic system for automated diagnosis. Finally, the output result of the image recognition model is interpreted and interpreted, and a basis for assisting in decision making is provided for doctors. The method realizes the intelligent processing of the thoracic surgery image analysis and diagnosis based on big data by collecting the big data, preprocessing, extracting the characteristics, training and optimizing the machine learning model and introducing the diagnosis system, and improves the accuracy and the efficiency of the diagnosis.
The current treatments available for complicated pleural effusions (CPE) include chest tube placement for drainage and IV antibiotics. If this fails and CPE occurs then in most patients thoracotomy is performed. Patients that are not surgical candidates have image guided catheter placement performed, sometimes multiple times. The American College of Chest Physicians (ACCP) formed a CPE panel and published guidelines for treating CPE. Percutaneous image-guided drainage is the most common approach for CPE. The panel recognizes the cumulative data that supports the use of fibrinolytics, VATS, and thoracotomy. The CPE panel acknowledged the lack of randomized clinical trials to determine efficacy and safety of these modalities in CPE and strongly encourages the research to take place.

Fibrinolytic therapy is a relatively noninvasive, easy to use, and is relatively inexpensive. If successful, it will prevent sepsis and septic shock, decrease hospital stay, morbidity and mortality and prevent any surgical procedures. Multiple doses of fibrinolytics have been used in CPE with no evidence of systemic anti-fibrinolytic activity. Complications with these medications are also very uncommon and only isolated instances are reported. The benefit from successful pleural drainage using these agents will decrease morbidity, mortality, surgical procedures, and hospital stay.
Mental health problems are common among parents of children with chronic pain and associated with worse outcomes for the child with chronic pain. However, the effect sizes of these associations between parent mental health and pediatric chronic pain vary widely across studies. The aim of this systematic review and meta-analysis was to generate pooled estimates of the (1) prevalence of mental health problems among parents of children with chronic pain and (2) associations between parent mental health and the (2a) presence of child chronic pain and (2b) functioning of children with chronic pain. Embase, MEDLINE, PsycINFO, Web of Science, and CINAHL were searched up to November 2022. Observational studies that examined symptoms or diagnoses of parent anxiety, depression, or general distress and the presence of child chronic pain and/or related functioning were included. From 32,848 records, 2 coders identified 49 studies to include in random-effects meta-analyses. The results revealed that mental health problems among parents of children with chronic pain were common (anxiety: 28.8% [95% CI 20.3-39.1]; depression: 20.0% [15.7-25.2]; general distress: 32.4% [22.7-44.0]). Poorer parent mental health was significantly associated with the presence of chronic pain (anxiety: OR = 1.91 [1.51-2.41]; depression: OR = 1.90 [1.51-2.38]; general distress: OR = 1.74 [1.47-2.05]) and worse related functioning (ie, pain intensity, physical functioning, anxiety and depression symptoms; r s = 0.10-0.25, all P s < 0.05) in children. Moderator analyses were generally nonsignificant or could not be conducted because of insufficient data. Findings support the importance of addressing parent mental health in the prevention and treatment of pediatric chronic pain.
The invention provides a miRNA-23a-5p inhibitor and application thereof in preparing a medicament for treating high-salt damage diseases. The miRNA-23a-5p inhibitor comprises any one of nucleotide sequences shown as (I), (II) or (III): (I) a nucleotide sequence shown as SEQ ID NO. 1; (II) a nucleotide sequence having at least 90% identity to the nucleotide sequence set forth in SEQ ID No. 1; (III) a nucleotide sequence obtained by modifying, substituting, adding or deleting one or more nucleotides in the nucleotide sequence shown in SEQ ID NO. 1. The miRNA-23a-5p can directly target the 3' -UTR of HSP70, and the miRNA-23a-5p inhibitor can be used for up-regulating the expression level of intracellular HSP70, enhancing the cell activity and promoting the cell proliferation in a hypertonic environment.
A multi-ply flushable wipe includes a ply having first and second exterior layers and a middle layer disposed therebetween. Each of the exterior layers includes at least 50% by weight natural fibers. When foam-formed, the middle layer includes at least 25% by weight natural fibers. In embodiments, the middle layer may include at least 75% by weight natural fibers. The middle layer also includes synthetic fibers that have a length within the range of 1 mm and 20 mm. The wipe may have a length weight weighted average fiber length of less than 4 mm and a wet CD strength of greater than 20 N/m. Each ply of the wipe may be formed by wetlaying the first and second exterior layers and a foam formed middle layer to form a web, imprinting the web with a structured fabric, and drying the web. The plies are then attached using a binder.
PCT No. PCT/EP94/03514 Sec. 371 Date May 2, 1996 Sec. 102(e) Date May 2, 1996 PCT Filed Oct. 26, 1994 PCT Pub. No. WO95/12666 PCT Pub. Date May 11, 1995The present invention relates to human foam cells generated in vitro from monocyte/macrophage related cell lines which give rise to an average intracellular cholesterol amount of at least 139+36 ug/mg cell protein as determined by HPLC, with said cholesterol being characterized by a degree of 46+6% of esterification as determined by HPLC. The invention also relates to monoclonal antibodies selected via said foam cells and which can be used for pharmaceutical and diagnostic purposes.
Disclosed herein are conditionally active multivalent target-binding proteins which comprise two binding moieties, two linkers, two target antigen binding domains, and a constant domain. Each binding moiety comprises non-CDR loops for masking the binding of a target antigen binding domain to its target and CDRs for binding a further target. The multivalent target-binding proteins are activated upon cleavage of the cleavable linkers. Also disclosed are pro immune modulating molecules comprising dual binding moieties comprising non-CDR loops and cleavable linkers, that prohibit the binding of a target binding domain to their targets (e.g., binding of an antibody to an immune modulatory target is masked by the dual binding moieties). The dual binding moieties further have specificity for a bulk serum protein or a dual binding moiety target (e.g., a tumor antigen, an immune modulatory protein). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.